Can biocompatible dialysis fluids improve outcomes in peritoneal dialysis patients?

Peritoneal Dialysis International

Volumn 25, Issue 3, 2005, Pages 230-233

  Woodrow, Graham ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

'BALANCE'; ADVANCED GLYCATION END PRODUCT; BICARBONATE; BIOLOGICAL MARKER; BUFFER; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; LACTIC ACID; OSMOTIC AGENT; PERITONEAL DIALYSIS FLUID;

ARTICLE; BIOCOMPATIBILITY; CELL FUNCTION; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HEMODIALYSIS; HUMAN; HYPEROSMOLARITY; IMMUNE RESPONSE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MEMBRANE DAMAGE; MESOTHELIUM CELL; PAIN; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; UREMIA;

EID: 19444377501     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500304     Document Type: Article

References (24)

1. Holmes CJ, Faict D. Peritoneal dialysis solution biocompatibility: definitions and evaluation strategies. Kidney Int Suppl 2003; 88:S50-6.
2. Di Paolo N, Garosi G, Petrini G, Traversari L, Rossi P. Peritoneal dialysis solution biocompatibitity testing in animals. Perit Dial Int 1995; 15(Suppl 3):S61-9.
3. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498-506.
4. Williams JD, Craig KJ, Topley N, von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane in patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
5. Williams JD, Craig KJ, von Ruhland C, Topley N, Williams G. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl 2003; 88: S43-9.
6. DeVriese AS, Mortier S, Lameire NH. Neoangiogenesis in the peritoneal membrane: does it play a role in ultrafiltration failure? Nephrol Dial Transplant 2001; 16:2143-5.
7. De Fijter CWH, Verbrugh HA, Peters EDJ, Oe PL, van der Meulen J, Verhoef J, et al. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. Clin Nephrol 1993; 39: 75-80.
8. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53:1061-7.
9. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
10. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, et al. Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney Int 2003; 64:1854-66.
11. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-39.
12. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
13. Wieslander A, Linden T. Glucose degradation products and cytotoxicity in PD fluids. Perit Dial Int 1996; 16(Suppl 1): S114-18.
14. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A. 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002; 62:697-703.
15. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe H, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
16. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 1999; 14:1541-9.
17. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al., on behalf of the Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
18. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
19. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranæus A, et al., on behalf of the Bicarbonate/Lactate Study Group. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59:1529-38.
20. Tranæus A, for the Bicarbonate/Lactate Study Group. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution - clinical benefits. Perit Dial Int 2000; 20:516-23.
21. Simonsen O, Wieslander A, Landgren C, Rippe B. Less infusion pain and elevated level of cancer antigen 125 by the use of a new more biocompatible PD fluid. Adv Perit Dial 1996; 12:156-60.
22. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248-55.
23. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63:298-305.
24. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized controlled trial. J Am Soc Nephrol 2002; 13:1307-20.